Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

224P - Immune characterization of de novo metastatic breast cancer

Date

08 Dec 2022

Session

Poster Display

Presenters

Mathilde Yernaux

Citation

Annals of Oncology (2022) 16 (suppl_1): 100105-100105. 10.1016/iotech/iotech100105

Authors

M. Yernaux1, S. Chretien2, F. Rothé3, X. Wang3, G. Rouas3, A. Boisson3, N. Kotecki3, A. Mailliez2, D. Larsimont3, D. Venet3, C. Sotiriou3, L. Buisseret3

Author affiliations

  • 1 ULB - UniversitŽ Libre de Bruxelles, Brussels/BE
  • 2 Centre Oscar Lambret, Lille/FR
  • 3 Institute Jules Bordet, Brussels/BE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 224P

Background

Breast cancer (BC) is mostly detected at an early stage but can be diagnosed with de novo (dn) metastases. Oligometastatic BC (OMBC) is distinguished from polymetastatic BC (PMBC) based on a limited disease burden usually defined by a cut-off of 5 metastases and is associated with a better prognosis. The immune system could be implicated in the control of the OMBC state by limiting metastatic dissemination. Here we compared tumour immune infiltrates in a cohort of dn OMBC and dn PMBC and correlated them with survival.

Methods

Clinicopathological characteristics at diagnosis of 115 dn OMBC and 117 dn PMBC patients were retrospectively collected. Tumour-infiltrating lymphocytes (TILs) were quantified on standard H&E staining. Immune infiltrates of 31 dn OMBC and 42 dn PMBC primary tumours were further characterized using multiplex multispectral immunochemistry (mIHC) allowing detection of CD4, CD8, FoxP3 T and CD20 B cells classified as intra-tumoral (i) or stromal (s) according to their localization. Epithelial cells were marked with pancytokeratin. Survival analyses were assessed using Cox’s proportional hazards models.

Results

In both cohorts, BC were mostly staged cT2 with lymph node involvement. Patients with dn OMBC had lower neutrophil/lymphocyte ratios, LDH and CA15-3 levels and showed a better outcome. No statistical differences were noted regarding TIL levels (median 5% in OMBC, 0% in PMBC) or their immune spatial distribution and most tumours were classified as “cold”. mIHC revealed that CD4 and CD8 T cells were the most represented TILs. Very few FoxP3 T and CD20 B cells were present. We noted a significantly higher infiltration of iCD4, iCD8 and iFoxP3 T cells in dn OMBC. Similar findings were found for sCD4 T cells (p<0.001). Median CD4/CD8 ratios in both compartments were significantly higher in dn OMBC (p=0.001). Of interest, each 10% increment of sCD8 T cells were associated with better OS (HR: 0.48, p=0.034) and PFS (HR: 0.57, p=0.047) only in dn OMBC. sCD4/CD8 and sCD8/FoxP3 ratios were also correlated with survival in dn OMBC. In both cohorts iCD20 B cells were associated with worse survival.

Conclusions

Here we show that CD8 T cells have prognostic value in dn OMBC but not in dn PMBC suggesting a potential role of immunotherapy in this setting, and it should be further investigated.

Legal entity responsible for the study

Institute Jules Bordet.

Funding

Association Jules Bordet.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.